Alterations in Nuclear Pore Architecture Allow Cancer Cell Entry into or Exit from Drug-Resistant Dormancy

被引:30
|
作者
Kinoshita, Yayoi [1 ]
Kalir, Tamara [1 ]
Rahaman, Jamal [2 ]
Dottino, Peter [2 ]
Kohtz, D. Stave [1 ,3 ]
机构
[1] Mt Sinai Sch Med, Dept Pathol, New York, NY 10029 USA
[2] Mt Sinai Sch Med, Dept Obstet Gynecol & Reprod Sci, New York, NY 10029 USA
[3] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA
来源
AMERICAN JOURNAL OF PATHOLOGY | 2012年 / 180卷 / 01期
基金
美国国家科学基金会;
关键词
CISPLATIN-INDUCED APOPTOSIS; EPITHELIAL OVARIAN-CANCER; GRADE SEROUS CARCINOMA; BREAST-CANCER; GROWTH ARREST; P62; COMPLEX; P53; GENE; CHEMOTHERAPY; EXPRESSION; OVEREXPRESSION;
D O I
10.1016/j.ajpath.2011.09.024
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Phenotypic diversity arises in tumors just as it does in developing organisms, and tumor recurrence frequently manifests from the selective survival of divergent drug-resistant cells. Although the expanding tumor cell population may be successfully targeted, drug-resistant cells may persist and sustain the tumor or enter dormancy before igniting a future relapse. Herein, we show that partial knockdown of nucleoporin p62 (NUP62) by small-interfering RNA confers cisplatin resistance to cultured high-grade ovarian carcinoma cells. Treatment with NUP62 small-interfering RNA and cisplatin leaves resistant cells in a state of dormancy; some dormant cells can be induced to proliferate by transient induction of NUP62 expression from an ectopic expression construct. In addition to suggesting functional links between nuclear pore complex architecture and cancer cell survival, the culture system provides a novel experimental window into the dynamics of tumor cell drug resistance and dormancy. (Am J Pathol 2012, 180:375-389; DOI: 10.1016/j.ajpath.2011.09.024)
引用
收藏
页码:375 / 389
页数:15
相关论文
共 50 条
  • [1] Drug-resistant cell lines in cancer
    Cinatl Jr, Jindrich
    Wass, Mark N.
    Michaelis, Martin
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [2] Mmp-2 facilitates prostate cancer entry into and exit from dormancy
    Nasr, Mostafa
    CANCER RESEARCH, 2022, 82 (12)
  • [3] Epigenetics, cell cycle and drug-resistant ovarian cancer
    Safuwan, Nur Arnida Mohammed
    Chivers, Pritlata
    Crook, Tim
    Syed, Nelofer
    Coley, Helen M.
    CANCER RESEARCH, 2012, 72
  • [4] Generation and molecular profiling of drug-resistant cancer cell lines
    He, Fang
    Pan, Pengwei
    Yuan, Zengjin
    Huang, Jingqi
    CANCER RESEARCH, 2016, 76
  • [5] On the Accuracy of Drug-Resistant Cell Population Estimation from Total Cancer Size Measurements
    Doosthosseini, Mahsa
    Hansen, Elsa
    Fathy, Hosam K.
    2019 18TH EUROPEAN CONTROL CONFERENCE (ECC), 2019, : 343 - 350
  • [6] Nuclear-uptake nanodrug delivery system for drug-resistant cancer therapy
    Huangxian Ju
    Science China Chemistry, 2015, 58 : 438 - 438
  • [7] Nuclear-uptake nanodrug delivery system for drug-resistant cancer therapy
    Ju, Huangxian
    SCIENCE CHINA-CHEMISTRY, 2015, 58 (03) : 438 - 438
  • [8] Nuclear-uptake nanodrug delivery system for drug-resistant cancer therapy
    Huangxian Ju
    Science China Chemistry, 2015, 58 (03) : 438
  • [9] Nuclear-uptake nanodrug delivery system for drug-resistant cancer therapy
    Huangxian Ju
    Science China Chemistry, 2015, (03) : 438 - 438
  • [10] The significance of lumican expression in ovarian cancer drug-resistant cell lines
    Klejewski, Andrzej
    Sterzynska, Karolina
    Wojtowicz, Karolina
    Swierczewska, Monika
    Partyka, Malgorzata
    Brazert, Maciej
    Nowicki, Michal
    Zabel, Maciej
    Januchowski, Radoslaw
    ONCOTARGET, 2017, 8 (43) : 74466 - 74478